Posts tagged: years

By GREG ALLMAIN Federal Way Mirror reporter April 4, 2012 · 10:46 AM With National Multiple Sclerosis (MS) Month having just ended in March, and the MS Walk coming up in Tacoma on April 14-15, there’s one Federal Way woman who is well acquainted with the disease. Deanna Kirkpatrick, 44, was diagnosed with the debilitating condition six years ago

A population-based study of neuromyelitis optica in Caucasians N.

Multiple sclerosis: clinical aspects Sunday, May 29, 2011, 12:00 – 13:00 Neuromyelitis optica spectrum disorder: the importance of NMO-IgG in clinical practice M. Radaelli, V

Purpose: To prospectively assess sensitivity and specificity of diffusion indexes of the corpus callosum (CC) for differentiating relapsing neuromyelitis optica (RNMO) from relapsing-remitting multiple sclerosis (RRMS), by using final clinical diagnosis as the reference standard. Materials and Methods: Participants provided informed consent; the study was approved by the institutional review board. Forty-six consecutive patients with RRMS (18 men, 28 women; mean age, 37.7 years; range, 18–58 years) and 26 consecutive patients with RNMO (two men, 24 women; mean age, 38.6 years; range, 19–59 years) underwent diffusion-tensor magnetic resonance imaging.

BACKGROUND: There have been few epidemiologic studies on neuromyelitis optica (NMO) and none used the recent 2006 diagnostic criteria. Here we describe the clinical, laboratory, MRI, and disability course of NMO in a French cohort of 125 patients. METHODS: We performed an observational, retrospective, multicenter study.

Recently, a disease-specific antibody was found in serum from patients with neuromyelitis optica (NMO), and its target antigen was identified as aquaporin 4 (AQP4) water channel protein. There is no clinical picture of pediatric cases with anti-AQP4 antibody, except one report from North America. Here, we report the clinical features of 18 Japanese anti-AQP4 antibody -positive patients with childhood-onset of NMO

Background: Neuromyelitis optica (NMO) frequently begins with a monofocal episode of optic neuritis or myelitis. A concept named high-risk syndrome (HRS) for NMO has been proposed for patients with monofocal episodes and NMO-IgG antibodies. Objective: To describe HRS patients and compare them with NMO patients

Background: Although brain lesions are now recognized more frequently in neuromyelitis optica spectrum disorder (NMOSD), most of them have been reported to be nonspecific and rarely symptomatic.

Background: Neuromyelitis optica (NMO) is an inflammatory disease associating optic neuritis and myelitis. Recently, several works showed that optical coherence tomography (OCT) should be an interesting method of disease severity.

Introduction: Recurrent NMO is an idiopathic inflammatory demyelinating disease of the CNS that preferentially affects the optical nerve and spinal cord. Only recently some studies reported RNMO in pediatric population. Objective: describe the clinical course of pediatric patients diagnosed with RNMO

Background: Using an anti-aquaporin-4 (AQP4) antibody assay discovered in 2005, Japanese patients with neuromyelitis optica (NMO) can easily be differentially diagnosed from those with opticospinal multiple sclerosis (MS).

Background: Neuromyelitis optica (NMO) is an inflammatory disorder of the central nervous system predominantly affecting the optic nerves and spinal cord with severe relapses resulting devastating disability.